Neurogene Stock Number Of Shares Shorted
| NGNE Stock | 22.73 0.09 0.40% |
Neurogene fundamentals help investors to digest information that contributes to Neurogene's financial success or failures. It also enables traders to predict the movement of Neurogene Stock. The fundamental analysis module provides a way to measure Neurogene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurogene stock.
Neurogene | Number Of Shares Shorted |
Neurogene Company Number Of Shares Shorted Analysis
Neurogene's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Neurogene Number Of Shares Shorted | 1.17 M |
Most of Neurogene's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurogene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Neurogene Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Neurogene is extremely important. It helps to project a fair market value of Neurogene Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Neurogene's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurogene's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurogene's interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Neurogene has 1.17 M of outstending shares currently sold short by investors. This is 63.28% lower than that of the Biotechnology sector and 76.96% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 75.04% higher than that of the company.
Neurogene Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurogene's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurogene could also be used in its relative valuation, which is a method of valuing Neurogene by comparing valuation metrics of similar companies.Neurogene is currently under evaluation in number of shares shorted category among its peers.
Neurogene ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurogene's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurogene's managers, analysts, and investors.Environmental | Governance | Social |
Neurogene Fundamentals
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (21.77) % | ||||
| Current Valuation | 211.85 M | ||||
| Shares Outstanding | 14.83 M | ||||
| Shares Owned By Insiders | 10.69 % | ||||
| Shares Owned By Institutions | 89.31 % | ||||
| Number Of Shares Shorted | 1.17 M | ||||
| Price To Book | 2.45 X | ||||
| Price To Sales | 363.58 X | ||||
| EBITDA | (52.29 M) | ||||
| Net Income | (36.32 M) | ||||
| Total Debt | 16.25 M | ||||
| Book Value Per Share | 11.93 X | ||||
| Cash Flow From Operations | (51.42 M) | ||||
| Short Ratio | 7.15 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 54.6 | ||||
| Number Of Employees | 91 | ||||
| Market Capitalization | 593.14 M | ||||
| Total Asset | 222.57 M | ||||
| Retained Earnings | (187.15 M) | ||||
| Working Capital | 177.38 M | ||||
| Net Asset | 222.57 M |
About Neurogene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurogene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurogene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurogene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out Neurogene Piotroski F Score and Neurogene Altman Z Score analysis. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.66) | Revenue Per Share 0.106 | Return On Assets (0.32) | Return On Equity (0.41) |
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.